Company Description
LIXTE Biotechnology Holdings, Inc., a clinical-stage pharmaceutical company, focuses on identifying targets for cancer drug development, and developing and commercializing cancer therapies.
Its lead product candidate, LB-100 is in phase 1b clinical trials combined with Atezolizumab for patients with microsatellite stable metastatic colon cancer.
The company’s Phase 1b portion of its advanced soft tissue sarcoma clinical trial seeks to determine appropriate dosing and toxicity for treating soft tissue sarcomas with combination of LB-100 and standard-of-care chemotherapy; and LB-100 combined with dostarlimab that is in phase 1b/2 for ovarian clear cell carcinoma.
The company has a clinical trial research agreement with the Netherlands Cancer Institute; collaboration agreement for an investigator-initiated clinical trial with the Spanish Sarcoma Group; and a development collaboration agreement with the Netherlands Cancer Institute.
Lixte Biotechnology Holdings, Inc. was founded in 2005 and is based in Pasadena, California.
| Country | United States |
| Founded | 2005 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 4 |
| CEO | Bastiaan van der Baan |
Contact Details
Address: 680 East Colorado Boulevard, Suite 180 Pasadena, California 91101 United States | |
| Phone | 631 830 7092 |
| Website | lixte.com |
Stock Details
| Ticker Symbol | LIXT |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001335105 |
| CUSIP Number | 539319202 |
| ISIN Number | US5393193017 |
| Employer ID | 20-2903526 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Bastiaan van der Baan M.Sc. | President, Chief Executive Officer and Chairman of the Board of Directors |
| Robert Neal Weingarten | Vice President and Chief Financial Officer |
| Eric J. Forman J.D. | Vice President and Chief Operating Officer |
| Johannes Henricus Matthias Schellens M.D., Ph.D. | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 2, 2024 | 8-K | Current Report |
| Nov 12, 2024 | 10-Q | Quarterly Report |
| Nov 5, 2024 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| Nov 5, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Nov 5, 2024 | DEF 14A | Other definitive proxy statements |
| Nov 1, 2024 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| Oct 23, 2024 | PRE 14A | Other preliminary proxy statements |
| Oct 23, 2024 | 8-K | Current Report |
| Oct 23, 2024 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Sep 5, 2024 | 8-K | Current Report |